JP5657638B2 - Trpa1調節因子としての縮合ピリミジンジオン誘導体 - Google Patents

Trpa1調節因子としての縮合ピリミジンジオン誘導体 Download PDF

Info

Publication number
JP5657638B2
JP5657638B2 JP2012501401A JP2012501401A JP5657638B2 JP 5657638 B2 JP5657638 B2 JP 5657638B2 JP 2012501401 A JP2012501401 A JP 2012501401A JP 2012501401 A JP2012501401 A JP 2012501401A JP 5657638 B2 JP5657638 B2 JP 5657638B2
Authority
JP
Japan
Prior art keywords
acetamide
thiazol
dioxo
pyrimidin
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012501401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521401A (ja
JP2012521401A5 (OSRAM
Inventor
サチン・スンダーラル・ショーダリ
スケールティ・クマル
アブラハム・トマス
ニシャ・パラグ・パティル
アショク・ボーサヘブ・カダム
ビシャル・ゴビンドラオ・デシュムク
サチン・バサントラオ・ドーネ
ラジェンドラ・プラカシュ・チカレ
ニーリマ・カイラトカー−ジョシ
インドラニル・ムコパデャイ
Original Assignee
グレンマーク ファーマシューティカルズ, エセ.アー.
グレンマーク ファーマシューティカルズ, エセ.アー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グレンマーク ファーマシューティカルズ, エセ.アー., グレンマーク ファーマシューティカルズ, エセ.アー. filed Critical グレンマーク ファーマシューティカルズ, エセ.アー.
Publication of JP2012521401A publication Critical patent/JP2012521401A/ja
Publication of JP2012521401A5 publication Critical patent/JP2012521401A5/ja
Application granted granted Critical
Publication of JP5657638B2 publication Critical patent/JP5657638B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012501401A 2009-03-23 2010-03-17 Trpa1調節因子としての縮合ピリミジンジオン誘導体 Expired - Fee Related JP5657638B2 (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
IN665/MUM/2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
US61/171,355 2009-04-21
IN2211/MUM/2009 2009-09-23
IN2212/MUM/2009 2009-09-23
IN2211MU2009 2009-09-23
IN2212MU2009 2009-09-23
US25194409P 2009-10-15 2009-10-15
US61/251,944 2009-10-15
US25326309P 2009-10-20 2009-10-20
US61/253,263 2009-10-20
IN2892/MUM/2009 2009-12-15
IN2892MU2009 2009-12-15
IN2891/MUM/2009 2009-12-15
IN2891MU2009 2009-12-15
US29446310P 2010-01-12 2010-01-12
US61/294,463 2010-01-12
US30024110P 2010-02-01 2010-02-01
US61/300,241 2010-02-01
PCT/IB2010/000553 WO2010109287A1 (en) 2009-03-23 2010-03-17 Fused pyrimidine-dione derivatives as trpa1 modulators

Publications (3)

Publication Number Publication Date
JP2012521401A JP2012521401A (ja) 2012-09-13
JP2012521401A5 JP2012521401A5 (OSRAM) 2013-04-18
JP5657638B2 true JP5657638B2 (ja) 2015-01-21

Family

ID=42780198

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012501401A Expired - Fee Related JP5657638B2 (ja) 2009-03-23 2010-03-17 Trpa1調節因子としての縮合ピリミジンジオン誘導体

Country Status (23)

Country Link
US (1) US9000159B2 (OSRAM)
EP (2) EP2411393B1 (OSRAM)
JP (1) JP5657638B2 (OSRAM)
KR (1) KR20110132575A (OSRAM)
CN (1) CN102361873B (OSRAM)
AP (1) AP3280A (OSRAM)
AU (1) AU2010227245B2 (OSRAM)
BR (1) BRPI1013559A2 (OSRAM)
CA (1) CA2756518A1 (OSRAM)
CL (2) CL2011002315A1 (OSRAM)
DK (1) DK2411393T3 (OSRAM)
EA (1) EA023857B1 (OSRAM)
ES (2) ES2551085T3 (OSRAM)
IL (1) IL215178A (OSRAM)
MX (1) MX2011009824A (OSRAM)
PE (1) PE20120774A1 (OSRAM)
PL (1) PL2411393T3 (OSRAM)
PT (1) PT2411393E (OSRAM)
SG (1) SG174402A1 (OSRAM)
SI (1) SI2411393T1 (OSRAM)
UA (1) UA108069C2 (OSRAM)
WO (1) WO2010109287A1 (OSRAM)
ZA (1) ZA201107648B (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018724B1 (ru) 2006-08-07 2013-10-30 Айронвуд Фармасьютикалз, Инк. Соединения индола
JP5657638B2 (ja) 2009-03-23 2015-01-21 グレンマーク ファーマシューティカルズ, エセ.アー. Trpa1調節因子としての縮合ピリミジンジオン誘導体
JP5694560B2 (ja) 2010-12-20 2015-04-01 グレンマーク ファーマシューティカルズ, エセ.アー. Trpa1アンタゴニストとしての2−アミノ−4−アリールチアゾール化合物
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
CA2836856A1 (en) 2011-06-13 2012-12-20 Glenmark Pharmaceuticals, S.A. Treatment of respiratory disorders using trpa1 antagonists
WO2012176143A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
WO2013014597A1 (en) 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
WO2013023102A1 (en) 2011-08-09 2013-02-14 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel trpa1
CA2857109A1 (en) 2011-12-05 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
CN104203236A (zh) 2012-01-17 2014-12-10 味之素株式会社 杂环酰胺衍生物和含有其的药物
CN104350058A (zh) 2012-06-08 2015-02-11 格兰马克药品股份有限公司 2-氨基-4-芳基噻唑化合物的酰胺及其盐
CA2884922C (en) 2012-10-01 2020-11-10 Orion Corporation N-prop-2-ynyl carboxamide derivatives and their use as trpa1 antagonists
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
JP2016537322A (ja) 2013-10-15 2016-12-01 グレンマーク ファーマシューティカルズ, エセ.アー. Trpa1アンタゴニスト及び鎮痛剤を含む医薬組成物
PT3064498T (pt) * 2013-10-30 2019-10-14 Shanghai hengrui pharmaceutical co ltd Derivados de pirazolopirimidona ou de pirrolotriazona, método de preparação dos mesmos, e aplicações farmacêuticas dos mesmos
CN103755705B (zh) * 2014-02-17 2017-02-15 上海佰特因医药科技有限公司 一种天然产物四甲基尿酸的全合成方法
EP3180342B1 (en) * 2014-08-11 2019-06-26 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
CN105001170A (zh) * 2015-07-13 2015-10-28 佛山市赛维斯医药科技有限公司 末端腈基取代的三氮唑亚砜类化合物、其制备方法及其用途
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
KR20200035043A (ko) * 2017-07-28 2020-04-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피리미돈 헤테로아릴 유도체를 제조하기 위한 방법 및 피리미돈 헤테로아릴 유도체의 중간체
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
CN108558836A (zh) * 2018-05-14 2018-09-21 东南大学 一类具有双重作用机制的dpp-4抑制剂及其用途
WO2023096915A1 (en) * 2021-11-24 2023-06-01 Slap Pharmaceuticals Llc Multicyclic compounds
US20250136587A1 (en) * 2022-02-03 2025-05-01 D. E. Shaw Research, Llc N3-substituted uracil compounds as trpa1 inhibitors
US20250214980A1 (en) * 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
CN114656473B (zh) * 2022-04-27 2023-09-29 成都施贝康生物医药科技有限公司 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656472B (zh) * 2022-04-27 2023-07-04 成都施贝康生物医药科技有限公司 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN118373832B (zh) * 2023-01-20 2025-01-28 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) * 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
WO2004014916A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
US7465581B2 (en) 2002-12-18 2008-12-16 The Scripps Research Institute ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons
JP2007522214A (ja) * 2004-02-11 2007-08-09 スミスクライン・ビーチャム・コーポレイション Pthアゴニスト
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US20090062258A1 (en) 2005-02-03 2009-03-05 Takeda Pharmaceutical Company Limited Fused pyrimidine derivative and use thereof
US20060291462A1 (en) * 2005-06-28 2006-12-28 Utstarcom, Inc. Method and apparatus using multiple application cards to comprise multiple logical network entities
TW201900217A (zh) 2005-12-22 2019-01-01 美商海卓勒生物科學公司 用於調節trpa1功能之化合物
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
WO2008094909A2 (en) 2007-01-29 2008-08-07 Xenon Pharmaceuticals Inc. Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
CA2691468C (en) * 2007-06-22 2017-05-09 Hydra Biosciences, Inc. Substituted xanthine compounds and methods to treat diseases mediated by trpa1
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CA2756535A1 (en) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as trpa1 modulators
JP5657638B2 (ja) 2009-03-23 2015-01-21 グレンマーク ファーマシューティカルズ, エセ.アー. Trpa1調節因子としての縮合ピリミジンジオン誘導体
SI2411397T1 (sl) 2009-03-23 2013-07-31 Glenmark Pharmaceuticals S.A. Izotiazolopirimidindionski derivati kot TRPA1 modulatorji
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
US20120088662A1 (en) 2009-06-18 2012-04-12 Basf Se Fungicidal mixtures
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
CN102574860A (zh) 2009-10-15 2012-07-11 辉瑞大药厂 吡咯并[2,3-d]嘧啶化合物
EP2311844A1 (en) 2009-10-15 2011-04-20 Interquim, S.A. Silyl polymeric benzoic acid ester compounds, uses, and compositions thereof
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
EP2483255B1 (en) 2010-07-13 2013-10-16 Novartis AG Oxazine derivatives and their use in the treatment of neurological disorders

Also Published As

Publication number Publication date
CA2756518A1 (en) 2010-09-30
IL215178A (en) 2015-01-29
PT2411393E (pt) 2014-02-21
UA108069C2 (uk) 2015-03-25
EP2708538A1 (en) 2014-03-19
HK1194742A1 (en) 2014-10-24
HK1166075A1 (en) 2012-10-19
EP2708538B1 (en) 2015-08-12
DK2411393T3 (da) 2014-04-07
EA023857B1 (ru) 2016-07-29
AU2010227245B2 (en) 2015-09-10
EP2411393B1 (en) 2014-01-22
MX2011009824A (es) 2012-01-25
BRPI1013559A2 (pt) 2016-04-12
SG174402A1 (en) 2011-10-28
AP3280A (en) 2015-05-31
CN102361873A (zh) 2012-02-22
EP2411393A1 (en) 2012-02-01
US20140128603A1 (en) 2014-05-08
US9000159B2 (en) 2015-04-07
ES2456515T3 (es) 2014-04-22
WO2010109287A1 (en) 2010-09-30
EP2411393A4 (en) 2012-08-01
CN102361873B (zh) 2014-07-09
AU2010227245A1 (en) 2011-09-22
AU2010227245A2 (en) 2011-10-27
AP2011005887A0 (en) 2011-10-31
ZA201107648B (en) 2012-07-25
PL2411393T3 (pl) 2014-06-30
SI2411393T1 (sl) 2014-03-31
EA201190143A1 (ru) 2012-04-30
ES2551085T3 (es) 2015-11-16
PE20120774A1 (es) 2012-06-27
CL2011002315A1 (es) 2012-04-09
CL2014001447A1 (es) 2014-10-17
JP2012521401A (ja) 2012-09-13
KR20110132575A (ko) 2011-12-08
IL215178A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
JP5657638B2 (ja) Trpa1調節因子としての縮合ピリミジンジオン誘導体
JP5612070B2 (ja) Trpa1調節因子としてのチエノピリミジンジオン誘導体
EP2411397B1 (en) Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
US8623880B2 (en) Fused pyrimidine-dione derivatives as TRPA1 modulators
WO2010125469A1 (en) Pyrimidinedione-fused heterocyclic compounds as trpa1 modulators
WO2011114184A1 (en) Amides of heterocyclic compounds as trpa1 inhibitors
WO2011132017A1 (en) Pyrido[3,4-d]pyrimidinyl acetamide derivatives as trpa1 modulators
HK1166075B (en) Fused pyrimidine-dione derivatives as trpa1 modulators
HK1166081B (en) Isothiazolo-pyrimidinedione derivatives as trpa1 modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140520

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140718

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141126

R150 Certificate of patent or registration of utility model

Ref document number: 5657638

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees